MAR 29, 2020 1:53 PM PDT

Improving ependymoma diagnostics

Have you ever heard of ependymoma? This rare form of brain cancer most commonly occurs in young children when tumors form from ependymal cells in the brain and spinal cord that line the cerebrospinal fluid passageways. Diagnosing ependymoma is particularly difficult and the medical community is lacking sufficient markers for identifying the disease. But new research published in the journal Autophagy from scientists at Kanazawa University hopes to provide insight that could improve diagnostics and potentially even treatment options.

Researchers Richard Wong and Mitsutoshi Nakada led a team to discover how a gene called TPR is connected to ependymoma. They demonstrated how 38% of ependymoma cases have elevated levels of TPR and investigated whether abnormal TPR levels lead to cancer progression in mice. They found that the TPR gene is vital for the progression of ependymoma tumors.

As Eureka Alert reports, “Deletion of the TPR protein is known to induce a process called autophagy within cells. Autophagy is initiated when a cell is under undue stress and results in the death of damaged cells. The patient tumor samples, with their high levels of TPR protein, showed little or no presence of autophagy. However, autophagy was remarkably high in the mice with TPR depletion. Ependymoma cells were thus spared of autophagic death due to the increased presence of TPR. These damaged cells continued to grow by circumventing the biological systems set up to keep them in check. The high TPR levels were also accompanied by an increase in HSF-1 and MTOR, molecules which are responsible for cell growth and survival.”

These findings provide an opportunity for scientists to target TPR as biomarkers, which can help both in diagnostic assessment and treatment for the cancer. The researchers also determined that inhibiting MTOR would serve in a similar way to treat ependymoma patients.

The authors hope their findings can combine their conclusions to a) help oncologists achieve a more comprehensive diagnosis and b) reduce TPR levels via drugs to limit tumor growth.

Sources: Autophagy, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 06, 2021
Cancer
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
JUN 06, 2021
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
The most recent results from the CODEBREAK 100 phase 2 clinical trial support the use of the drug sotorasib to reduce tu ...
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
JUN 29, 2021
Cancer
Heart Failure Linked to Increased Cancer Risk
JUN 29, 2021
Heart Failure Linked to Increased Cancer Risk
A study by researchers in Germany suggests that patients with heart failure are more likely to develop cancer than those ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
SEP 06, 2021
Drug Discovery & Development
Antibiotics Increase Colon Cancer Risk by 17%
SEP 06, 2021
Antibiotics Increase Colon Cancer Risk by 17%
People who take antibiotics are at an increased risk of developing colon cancer within five to ten years. The research w ...
Loading Comments...